AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
According to a new subgroup analysis from the pivotal Phase III MURANO trial, 83 percent of patients given the combination maintained undetectable minimal residual disease (uMRD) and were progression-free at 13.8 months of follow-up.
Also of note, patient best uMRD response rates were consistent independent of risk factors, including 17p deletion, IGVH mutation and TP53 mutation, the firm noted.
“In this analysis of MRD data in patients with chronic lymphocytic leukaemia given venetoclax in combination with rituximab, high and durable undetectable MRD rates were achieved in peripheral blood at the end of combination treatment assessment regardless of the risk features,” said Peter Hillmen, Professor of Experimental Haematology, Leeds Teaching Hospital in the UK, and lead investigator of the MURANO study.
Read more: http://www.pharmatimes.com/news/abbvie_unveils_high_undetectable_disease_rates_for_venetoclaxrituximab_combo_1240372
According to a new subgroup analysis from the pivotal Phase III MURANO trial, 83 percent of patients given the combination maintained undetectable minimal residual disease (uMRD) and were progression-free at 13.8 months of follow-up.
Also of note, patient best uMRD response rates were consistent independent of risk factors, including 17p deletion, IGVH mutation and TP53 mutation, the firm noted.
“In this analysis of MRD data in patients with chronic lymphocytic leukaemia given venetoclax in combination with rituximab, high and durable undetectable MRD rates were achieved in peripheral blood at the end of combination treatment assessment regardless of the risk features,” said Peter Hillmen, Professor of Experimental Haematology, Leeds Teaching Hospital in the UK, and lead investigator of the MURANO study.
Read more: http://www.pharmatimes.com/news/abbvie_unveils_high_undetectable_disease_rates_for_venetoclaxrituximab_combo_1240372